Chronic Kidney Disease

After more than 7 hours of discussion, the Cardiovascular and Renal Drugs Advisory Committee of the FDA voted against approval of roxadustat for the treatment of anemia due to chronic kidney disease for patients not on dialysis and on dialysis.

Ziltivekimab (Novo Nordisk) vs. placebo for reduction of inflammatory and thrombotic biomarker levels.

Following an intracerebral hemorrhage, decreased estimated glomerular filtration rate correlated with poor outcomes, according to study results published in Neurology.

The presence of metabolic acidosis increased the risk for major adverse cardiovascular events in patients with non-dialysis dependent chronic kidney disease, study findings showed.

In this video perspective, Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, offers a review of the Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases workshop, held June 18 to 19 in Dallas.

The FDA approved Kerendia for reducing the risk for kidney and heart complications among adults with chronic kidney disease associated with type 2 diabetes.

The FDA approved Kerendia for reducing the risk for kidney and heart complications among adults with chronic kidney disease associated with type 2 diabetes.

Iron deficiency was associated with all-cause mortality and major adverse cardiovascular events regardless of whether anemia was also present, results of a multinational study of patients with chronic kidney disease showed.

Specific markers of periodontal disease were associated with eGFR decline during a 6-year period, according to a study of Hispanic and Latino patients who underwent full dental examination at sites across the United States.

In this video perspective, Ian de Boer, MD, MS, discusses the connection between chronic kidney disease and cardiometabolic disease.